BioReliance, the biologics and early development services business of SAFC, has signed an agreement to acquire Agilent Technologies’ colonies for the Big Blue transgenic rodent mutation (TRM) assay and a license to its associated trademark.   TRM assays measure mutation frequency in any tissue and are the first in vivo genetic toxicology mutation assays to be approved by the Organization for Economic Co-Operation and Development (OECD). BioReliance now owns Big Blue mutation models and is the ex...